Literature DB >> 25130456

Differential partial activation phenotype and production of tumour necrosis factor-α by conventional dendritic cells in response to lipopolysaccharide in HIV+ viraemic subjects and HIV+ controllers.

R Camacho-Sandoval1, P M Del Río Estrada, A Rivero-Arrieta, G Reyes-Terán, L C Bonifaz.   

Abstract

HIV(+) subjects are reported to have increased soluble CD14 (sCD14) in plasma, an indicator of microbial translocation. We evaluated if microbial translocation has a differential impact on the activation and function of conventional dendritic cells (cDC) from viraemic HIV(+) subjects and HIV(+) controllers (CTs). The HIV(+) subjects were classified into two groups according to their plasma viral load (pVL): CT and viraemic. Subjects without HIV were included as controls (HIV(-) ). The frequencies and phenotypes of cDC from these subjects were evaluated by multi-parameter flow cytometry. In addition, peripheral blood mononuclear cells (PBMCs) were stimulated with lipopolysaccharide (LPS) or single-stranded RNA40 (ssRNA40), the phenotype of the cDC and the intracellular production of tumour necrosis factor (TNF)-α by the cDC were evaluated by flow cytometry. We observed a partial activation phenotype for the cDC in the viraemic subjects and CTs ex vivo and after LPS activation, which showed differences in the expression of CD40 and CD86. Furthermore, in response to LPS the cDC from the viraemic subjects produced more TNF-α compared to the cDC from CTs. Interestingly, the percentage of TNF-α(+) cDC was found to be correlated positively with the pVL. The partial activation of cDC and the over-production of TNF-α in response to LPS in viraemic HIV(+) subjects might be related to the increased chronic activation observed in these subjects. In contrast, cDC from CTs seem to have a regulated response to LPS, indicating that they respond differently to chronic immune activation. These results may have implications in the development of HIV therapies and vaccines using DC.
© 2014 British Society for Immunology.

Entities:  

Keywords:  HIV+ controllers (CTs); TNF-α; conventional dendritic cells (cDC); microbial translocation

Mesh:

Substances:

Year:  2014        PMID: 25130456      PMCID: PMC4238876          DOI: 10.1111/cei.12430

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  70 in total

Review 1.  Dendritic cell subsets in health and disease.

Authors:  Hideki Ueno; Eynav Klechevsky; Rimpei Morita; Caroline Aspord; Tinghua Cao; Toshimichi Matsui; Tiziana Di Pucchio; John Connolly; Joseph W Fay; Virginia Pascual; A Karolina Palucka; Jacques Banchereau
Journal:  Immunol Rev       Date:  2007-10       Impact factor: 12.988

2.  Different subsets of peripheral blood dendritic cells show distinct phenotypic and functional abnormalities in HIV-1 infection.

Authors:  María Almeida; Miguel Cordero; Julia Almeida; Alberto Orfao
Journal:  AIDS       Date:  2005-02-18       Impact factor: 4.177

3.  Low CD83, but normal MHC class II and costimulatory molecule expression, on spleen dendritic cells from HIV+ patients.

Authors:  D McIlroy; B Autran; J P Clauvel; E Oksenhendler; P Debré; A Hosmalin
Journal:  AIDS Res Hum Retroviruses       Date:  1998-04-10       Impact factor: 2.205

4.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

5.  Type I interferon contributes to CD4+ T cell depletion induced by infection with HIV-1 in the human thymus.

Authors:  Vijay Sivaraman; Liguo Zhang; Lishan Su
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

6.  Evidence of dysregulation of dendritic cells in primary HIV infection.

Authors:  Rachel Lubong Sabado; Meagan O'Brien; Abhignya Subedi; Li Qin; Nan Hu; Elizabeth Taylor; Oliver Dibben; Andrea Stacey; Jacques Fellay; Kevin V Shianna; Frederick Siegal; Michael Shodell; Kokila Shah; Marie Larsson; Jeffrey Lifson; Arthur Nadas; Michael Marmor; Richard Hutt; David Margolis; Donald Garmon; Martin Markowitz; Fred Valentine; Persephone Borrow; Nina Bhardwaj
Journal:  Blood       Date:  2010-08-06       Impact factor: 22.113

7.  CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

Authors:  Z Liu; W G Cumberland; L E Hultin; A H Kaplan; R Detels; J V Giorgi
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-08-01

8.  Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.

Authors:  Jeffrey A Martinson; Alejandro Roman-Gonzalez; Allan R Tenorio; Carlos J Montoya; Carolyne N Gichinga; Maria T Rugeles; Mark Tomai; Arthur M Krieg; Smita Ghanekar; Linda L Baum; Alan L Landay
Journal:  Cell Immunol       Date:  2008-03-10       Impact factor: 4.868

Review 9.  Designing vaccines based on biology of human dendritic cell subsets.

Authors:  Karolina Palucka; Jacques Banchereau; Ira Mellman
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

Review 10.  Characteristics of plasmacytoid dendritic cell and CD4+ T cell in HIV elite controllers.

Authors:  Jean-Philippe Herbeuval; Nikaïa Smith; Jacques Thèze
Journal:  Clin Dev Immunol       Date:  2012-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.